# Plain Language Summary: Make Medicine in America Again Act

This bill gives pharmaceutical companies significant tax breaks to encourage them to manufacture drugs and drug ingredients inside the United States. The main incentive is a tax credit worth 50 percent of what companies spend on pharmaceutical manufacturing activities here—meaning if a company spends $100 million on wages, equipment, and other manufacturing costs, they get a $50 million tax credit to reduce what they owe the government.

The bill also allows pharmaceutical manufacturers to immediately write off the full cost of new manufacturing equipment and facilities on their taxes, rather than spreading those costs over many years. This means companies can reduce their tax bills much faster when they invest in new factories or equipment. These tax breaks apply to spending on employee wages (including health insurance costs), equipment and machinery, and other direct costs related to making pharmaceuticals and the active ingredients that go into them.

For everyday people, the intended effect is that these tax incentives should make it more attractive for pharmaceutical companies to build and expand manufacturing plants in America rather than overseas. In theory, this could mean more domestic drug production, potentially more jobs in manufacturing, and possibly less dependence on imported medications. However, the actual impact depends on whether companies actually use these tax breaks to build new facilities or whether they primarily benefit from reduced taxes on operations they would have done anyway. The bill doesn't guarantee drug prices will go down or that medications will become more affordable—it simply reduces the tax burden on pharmaceutical manufacturers who produce drugs domestically.

Make Medicine in America Again Act

Mooney, Alexander X.

Make Medicine in America Again Act This bill provides tax incentives for the manufacture of pharmaceutical property, equipment, buildings, or facilities in the United States. Specifically it allows bonus depreciation for such property and a business-related tax credit for 50% of expenditures for (1) wages for services performed in a U.S. pharmaceutical manufacturing business, (2) the tangible personal property of such a business, and (3) any direct or indirect costs paid or incurred in a U.S. pharmaceutical manufacturing business.